Karabulut Yusuf
Division of Rheumatology, Doruk Private Hospital, Bursa, Turkey.
Eur J Rheumatol. 2021 Oct;8(4):223-227. doi: 10.5152/eurjrheum.2021.20160.
Neurological complications of BD (neuro-Behçet's disease [NBD]) are life-threatening and disabling manifestations. Neurological involvement occurs in approximately 5% to 18% of patients with BD. Most patients with NBD respond well to glucocorticoids, cyclophosphamide, or anti-tumor necrosis factors (TNFs), but there are some resistant cases refractory to these drugs. This study aims to summarize the existing data on the management of NBD, with special focus on patients resistant to anti-TNFs. The study included a short review of early treatment steps. In addition to a literature review of treatment with non-TNF biologics, we present 2 NBD cases with neurological involvement that are resistant to standard high-dose steroid therapy and anti-TNF treatment. Both patients responded well to the tocilizumab therapy, and there was no serious adverse event.
白塞病的神经系统并发症（神经白塞病 [NBD]）是危及生命且会导致残疾的表现。约5%至18%的白塞病患者会出现神经系统受累。大多数神经白塞病患者对糖皮质激素、环磷酰胺或抗肿瘤坏死因子（TNF）治疗反应良好，但也有一些病例对这些药物耐药。本研究旨在总结神经白塞病治疗的现有数据，特别关注对抗TNF药物耐药的患者。该研究包括对早期治疗步骤的简要回顾。除了对非TNF生物制剂治疗的文献综述外，我们还介绍了2例有神经系统受累且对标准大剂量类固醇治疗和抗TNF治疗耐药的神经白塞病病例。两名患者对托珠单抗治疗反应良好，且未出现严重不良事件。
